ArticleMolecular cytogenetics2016
Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors.
Article in Molecular cytogenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Gene Expression Analysis of (Paired) Primary and Relapsed Wilms Tumor Samples to Unravel the Underlying Factors Driving Tumor Recurrence.Cancer medicine · 2025Article
- PLCG2, A Regulator of Lung Adenocarcinoma Proliferation and Migration Associated with Immune Infiltration.Current cancer drug targets · 2025Article
- Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2.Acta biochimica et biophysica Sinica · 2024Article
- Teratoma-associated and so-called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features.Histopathology · 2024Article
- Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.Clinical epigenetics · 2023Article
- Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms Tumors.Cancers · 2022Article
- Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.Cell reports. Medicine · 2022Article
- A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.Journal of ovarian research · 2022Article
- MEX3A knockdown inhibits the tumorigenesis of colorectal cancer via modulating CDK2 expression.Experimental and therapeutic medicine · 2021Article
- The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51.PLoS biology · 2021Article
- Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa-miR-6887-3p.Cancer communications (London, England) · 2021Article
- Oncogenic Potential of the Dual-Function Protein MEX3A.Biology · 2021Review
- The effects of MEX3A knockdown on proliferation, apoptosis and migration of osteosarcoma cells.Cancer cell international · 2021Article
- MEX3A contributes to development and progression of glioma through regulating cell proliferation and cell migration and targeting CCL2.Cell death & disease · 2021Article
- MEX3A suppresses proliferation and EMT via inhibiting Akt signaling pathway in cervical cancer.American journal of cancer research · 2021Article
- MicroRNA-139-5p Suppresses Cell Malignant Behaviors in Breast Cancer through Targeting MEX3A.Computational and mathematical methods in medicine · 2021Article
- Golgi α1,2-mannosidase I induces clustering and compartmentalization of CD147 during epithelial cell migration.Cell adhesion & migration · 2020Article
- Article
- Chromodomain-helicase-DNA-binding protein 1-like (CHD1L) silencing inhibits gastric cancer cell proliferation, invasion, and migration.Translational cancer research · 2020Article
- MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWilms tumor (WT) has a not completely elucidated pathogenesis. DNA copy number alterations (CNAs) are common in cancer, and often define key pathogenic events. The aim of this work was to investigate CNAs in order to disclose new candidate genes for Wilms tumorigenesis.
resultsArray-CGH of 50 primary WTs without pre-chemotherapy revealed a few recurrent CNAs not previously reported, such as 7q and 20q gains, and 7p loss. Genomic amplifications were exclusively detected in 3 cases of WTs that later relapsed, which also exhibited an increased frequency of gains affecting a 16.2 Mb 1q21.1-q23.2 region, losses at 11p, 11q distal, and 16q, and WT1 deletions. Conversely, aneuploidies of chromosomes 13 and 19 were found only in WTs without further relapse. The 1q21.1-q23.2 gain associated with WT relapse harbours genes such as CHD1L, CRABP2, GJA8, MEX3A and MLLT11 that were found to be over-expressed in WTs. In addition, down-regulation of genes encompassed by focal deletions highlighted new potential tumor suppressors such as CNKSR1, MAN1C1, PAQR7 (1p36), TWIST1, SOSTDC1 (7p14.1-p12.2), BBOX and FIBIN (11p13), and PLCG2 (16q).
conclusionThis study confirmed the presence of CNAs previously related to WT and characterized new CNAs found only in few cases. The later were found in higher frequency in relapsed cases, suggesting that they could be associated with WT progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.